Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.1%

17 terminated/withdrawn out of 130 trials

Success Rate

82.8%

-3.8% vs industry average

Late-Stage Pipeline

6 trials in Phase 3/4

Results Transparency

84%

69 of 82 completed trials have results

Key Signals

16 recruiting69 with results7 terminated10 withdrawn

Enrollment reporting

Analytics

N/A

39(43.8%)

Phase 2

35(39.3%)

Phase 3

6(6.7%)

Phase 1

4(4.5%)

Phase 1/2

4(4.5%)

Early Phase 1

1(1.1%)

89Total

N/A(39)

Phase 2(35)

Phase 3(6)

Phase 1(4)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (130)

Showing 20 of 130 trials

NCT05415527Not ApplicableCompleted

Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management

Role: lead

NCT05720910Not ApplicableActive Not Recruiting

Streamlined Geriatric and Oncological Evaluation Based On IC Technology

Role: lead

NCT02534649Not ApplicableRecruiting

Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

Role: lead

NCT02789384Not ApplicableRecruiting

CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.

Role: lead

NCT04913259Not ApplicableCompleted

Remote Monitoring for Ambulatory Care of Elderly Patients With Cancer

Role: lead

NCT04968106Phase 2Active Not Recruiting

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Role: lead

NCT05346848Phase 2Recruiting

Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer

Role: lead

NCT06524583Phase 2Recruiting

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Role: collaborator

NCT07614620Not ApplicableRecruiting

Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer

Role: lead

NCT03357120Not ApplicableCompleted

Circulating Tumor DNA After Neoadjuvant Chemotherapy

Role: lead

NCT04906187Not ApplicableCompleted

Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery

Role: lead

NCT02704832Not ApplicableCompleted

Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)

Role: lead

NCT03915678Phase 2Active Not Recruiting

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Role: lead

NCT04258137Not ApplicableActive Not Recruiting

Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study

Role: lead

NCT04874311Phase 2Active Not Recruiting

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Role: lead

NCT04113226Phase 2Completed

Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma

Role: collaborator

NCT05630105Suspended

Cancer Risk Assessment in Patients With a Constitutional Alteration of the PTEN Gene

Role: lead

NCT04807816Phase 2Completed

Targeting ATR in Soft-tissue Sarcomas

Role: lead

NCT03784014Phase 3Completed

Molecular Profiling of Advanced Soft-tissue Sarcomas

Role: collaborator

NCT04095208Phase 2Completed

Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

Role: lead